A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs AMG-355 (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Amgen
Most Recent Events
- 05 Jun 2025 Planned End Date changed from 4 Jan 2029 to 22 Dec 2028.
- 05 Jun 2025 Planned primary completion date changed from 15 Mar 2028 to 2 Mar 2028.
- 15 May 2025 Planned End Date changed from 13 Feb 2028 to 4 Jan 2029.